Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.71 |
| ▸ | PRKCG | P05129 | 1/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.56 |
| ▸ | CETP | P11597 | 1/20 | 0.55 |
| ▸ | RORC | P51449 | 3/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 7/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12558108 | 1.00 | PTPN1 (0.71) | PTPN1PRKCGPRKCDCETPRORC | |
| SCHEMBL13876991 | 1.00 | PTPN1 (0.71) | PTPN1PRKCGPRKCDCETPRORC | |
| SCHEMBL12558130 | 0.94 | PTPN1 (0.69) | PTPN1PRKCGPRKCDCETPRORC | |
| SCHEMBL12558179 | 0.91 | PTPN1 (0.69) | PTPN1PRKCGPRKCDCETPRORC | |
| SCHEMBL12558182 | 0.91 | PTPN1 (0.71) | PTPN1PRKCGPRKCDCETPRORC | |
| SCHEMBL12558172 | 0.91 | PTPN1 (0.70) | PTPN1PRKCGPRKCDCETPRORC | |
| SCHEMBL12557912 | 0.90 | PRKCG (0.63) | PRKCGPRKCDCETPRORCTRPV1 | |
| SCHEMBL14628338 | 0.90 | PRKCG (0.63) | PRKCGPRKCDCETPRORCTRPV1 | |
| SCHEMBL12558177 | 0.90 | PTPN1 (0.69) | PTPN1PRKCGPRKCDCETPRORC | |
| SCHEMBL12558181 | 0.90 | PTPN1 (0.69) | PTPN1PRKCGPRKCDCETPRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144069-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2011-06-16 | — | — | US | disclosed |
| US-20090105203-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105203-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, CCL11 | PTPN1 3699/4885PRKCG 3008/4885PRKCD 3851/4885 |
| US-20110144069-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, CCL11 | PTPN1 3699/4885PRKCG 3008/4885PRKCD 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.